spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  phosphoinositide 

 HSMN NewsFeed - 2 Apr 2019
Petra Pharma Strengthens Management Team with Recent Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Mar 2019
Petra Pharma announces licensing agreement with Takeda Pharmaceutical Company
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Mar 2018
Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Jun 2014
Curis Announces Executive Management Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jul 2012
Infinity Announces New Addition to Senior Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2011
Infinity Announces Appointment of Joshua Hamermesh as Vice President, Business and Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2011
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 9 Nov 2010
Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2010
Infinity Announces That Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 21 Jul 2010
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2009
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2009
Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Aug 2009
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 13 Feb 2008
Calistoga Pharmaceuticals Announces Appointment of R. Lee Douglas, 22-Year Biotechnology/Pharmaceutical Industry Veteran, to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
Calistoga Pharmaceuticals Announces Completion of Its Series A Financing -- Investors Increased Funding by 25% to Total $26.2 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Mar 2007
Exelixis Files IND Application for XL147
Biopharmaceuticals Oncology
Return to NewsFeed  
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!